Bridget Hodkinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bridget Hodkinson has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Ronald Anderson
Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa
7 shared publications - Eustasius Musenge
Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg
6 shared publications - Pieter Willem Adriaan Meyer
Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa
6 shared publications - Mohammed Tikly
Division of Rheumatology, Department of Internal Medicine Faculty of Health Sciences, University of the Witwatersrand Johannesburg South Africa
5 shared publications Mohammed Tikly
Division of Rheumatology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 shared publicationsM. Tikly
Division of Rheumatology, Department of Medicine, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa
3 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7383
Genomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a strong genetic component, and lupus nephritis (LN) represents one of its most common and severe organ-specific manifestations. This review synthesises current evidence on the genetic architecture of SLE and LN, with a particular focus on identifying shared and distinct genetic susceptibility loci and highlighting knowledge and data gaps in highly burdened African populations. Across studies, most risk loci, including HLA-DRB1, TNFSF4, IRF5, STAT4, TNFAIP3, BANK1, BLK, ITGAM, and FcγR2A/FcγR3A, converge on key immune pathways such as antigen presentation, type I IFN signalling, B-cell activation, and immune complex clearance. The findings support a substantial genomic overlap between SLE and LN, with most variants contributing to systemic immune dysregulation rather than kidney-specific susceptibility. A limited number of loci, including PDGFRA, HAS2, and SLC5A11, have been implicated in renal involvement, while APOL1 G1/G2 risk variants are associated with renal disease progression and adverse kidney outcomes among individuals of African ancestry. Despite these advances, relatively few loci have been definitively linked to LN independent of SLE, reflecting both biological overlap and limitations in study design. Moreover, the existing literature is heavily skewed toward European, Asian, and admixed populations, with minimal representation of continental African cohorts. Given the high genetic diversity and disproportionate disease burden in African populations, this represents a critical knowledge gap. Improved inclusion of diverse populations, coupled with high-resolution genomic and functional studies, will be essential to refine causal variant identification and enhance understanding of disease mechanisms. Ultimately, insights into population-specific genetic risk may enable earlier identification of high-risk individuals and support the development of precision medicine strategies for SLE, specifically LN.
- 18 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7383
Open AccessGenomic Landscape of Systemic Lupus Erythematosus and Lupus Nephritis Globally and the Gaps in Africa
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a strong genetic component, and lupus nephritis (LN) represents one of its most common and severe organ-specific manifestations. This review synthesises current evidence on the genetic architecture of SLE and LN, with a particular focus on identifying shared and distinct genetic susceptibility loci and highlighting knowledge and data gaps in highly burdened African populations. Across studies, most risk loci, including HLA-DRB1, TNFSF4, IRF5, STAT4, TNFAIP3, BANK1, BLK, ITGAM, and FcγR2A/FcγR3A, converge on key immune pathways such as antigen presentation, type I IFN signalling, B-cell activation, and immune complex clearance. The findings support a substantial genomic overlap between SLE and LN, with most variants contributing to systemic immune dysregulation rather than kidney-specific susceptibility. A limited number of loci, including PDGFRA, HAS2, and SLC5A11, have been implicated in renal involvement, while APOL1 G1/G2 risk variants are associated with renal disease progression and adverse kidney outcomes among individuals of African ancestry. Despite these advances, relatively few loci have been definitively linked to LN independent of SLE, reflecting both biological overlap and limitations in study design. Moreover, the existing literature is heavily skewed toward European, Asian, and admixed populations, with minimal representation of continental African cohorts. Given the high genetic diversity and disproportionate disease burden in African populations, this represents a critical knowledge gap. Improved inclusion of diverse populations, coupled with high-resolution genomic and functional studies, will be essential to refine causal variant identification and enhance understanding of disease mechanisms. Ultimately, insights into population-specific genetic risk may enable earlier identification of high-risk individuals and support the development of precision medicine strategies for SLE, specifically LN.
- Open Access
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Musculoskeletal Disorders
- Vol. 4, 1882572
High burden of fatigue amongst socioeconomically disadvantaged South Africans with rheumatoid arthritis
Background: Fatigue substantially affects quality of life in rheumatoid arthritis (RA), yet evidence from sub-Saharan Africa is limited. This study determined the prevalence of fatigue and factors associated with severe fatigue among South African patients with RA. Methods: Consecutive adults with RA were drawn from a registry at a tertiary hospital for this cross-sectional analysis. Demographic and socioeconomic characteristics, disease activity, treatment, comorbidities, and patient-reported outcomes, including the Brief Pain Inventory, Health Assessment Questionnaire–Disability Index, EuroQol 5-Dimension questionnaire, and Hospital Anxiety and Depression Scale, were collected. Fatigue was assessed using the 13-item Functional Assessment of Chronic Illness Therapy–Fatigue scale. Any fatigue was defined as a FACIT-F score n = 516), severe fatigue was independently associated with current smoking [adjusted odds ratio (aOR) 1.78, 95% CI 1.14–2.79], multimorbidity (aOR 2.22, 95% CI 1.40–3.53), problems with usual activities (aOR 1.91, 95% CI 1.02–3.60), pain severity (aOR 1.23 per point, 95% CI 1.06–1.42), pain interference (aOR 1.18 per point, 95% CI 1.04–1.35), anxiety symptoms (HADS-A ≥ 11; aOR 3.13, 95% CI 1.94–5.06), and depressive symptoms (HADS-D ≥ 11; aOR 1.96, 95% CI 1.22–3.16). Conclusion: Fatigue was highly prevalent in this socioeconomically disadvantaged RA cohort, with more than two-fifths meeting the study definition of severe fatigue. Severe fatigue was associated with smoking, multimorbidity, limitations in usual activities, pain, anxiety, and depression. These findings support assessment of physical, psychological, behavioral, and comorbidity-related factors in patients with RA who report fatigue.
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Musculoskeletal Disorders
- Vol. 4, 1882572
Open AccessHigh burden of fatigue amongst socioeconomically disadvantaged South Africans with rheumatoid arthritis
Background: Fatigue substantially affects quality of life in rheumatoid arthritis (RA), yet evidence from sub-Saharan Africa is limited. This study determined the prevalence of fatigue and factors associated with severe fatigue among South African patients with RA. Methods: Consecutive adults with RA were drawn from a registry at a tertiary hospital for this cross-sectional analysis. Demographic and socioeconomic characteristics, disease activity, treatment, comorbidities, and patient-reported outcomes, including the Brief Pain Inventory, Health Assessment Questionnaire–Disability Index, EuroQol 5-Dimension questionnaire, and Hospital Anxiety and Depression Scale, were collected. Fatigue was assessed using the 13-item Functional Assessment of Chronic Illness Therapy–Fatigue scale. Any fatigue was defined as a FACIT-F score n = 516), severe fatigue was independently associated with current smoking [adjusted odds ratio (aOR) 1.78, 95% CI 1.14–2.79], multimorbidity (aOR 2.22, 95% CI 1.40–3.53), problems with usual activities (aOR 1.91, 95% CI 1.02–3.60), pain severity (aOR 1.23 per point, 95% CI 1.06–1.42), pain interference (aOR 1.18 per point, 95% CI 1.04–1.35), anxiety symptoms (HADS-A ≥ 11; aOR 3.13, 95% CI 1.94–5.06), and depressive symptoms (HADS-D ≥ 11; aOR 1.96, 95% CI 1.22–3.16). Conclusion: Fatigue was highly prevalent in this socioeconomically disadvantaged RA cohort, with more than two-fifths meeting the study definition of severe fatigue. Severe fatigue was associated with smoking, multimorbidity, limitations in usual activities, pain, anxiety, and depression. These findings support assessment of physical, psychological, behavioral, and comorbidity-related factors in patients with RA who report fatigue.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1)
Cigarette smoking habits and attitudes among rheumatoid arthritis patients at a tertiary centre in South Africa
Background: People living with rheumatoid arthritis (RA) who smoke cigarettes are known to have worse outcomes with regard to disease control, extra-articular complications and comorbidities. Data regarding this from sub-Saharan Africa is lacking. This study aims to describe the prevalence of cigarette smoking and explore disease control, comorbidities and attitudes of smoking among RA patients in an outpatient clinic at a tertiary hospital. Methods: A cross-sectional study of consenting adult outpatients with RA was conducted. Demographic, clinical and patient-reported outcome measures, together with a questionnaire about smoking and Fagerström test for nicotine dependence, were collated. Results: Of 632 patients (536 female participants), the mean (standard deviation) age and disease duration were 55.4 (13.0) and 10.1 (9.3) years, and 74.1% had two or more comorbidities. Of 218 (34.5%) smokers, more men smoked (p = 0.0002). Compared to non-smokers, smokers had lower body mass index (p = 0.01), higher incidence of chronic obstructive pulmonary disease (p < 0.005) and rheumatoid factor positivity (p = 0.006), and higher anxiety scores (p = 0.048) with more impairment in usual activities (p = 0.05). No significant differences in disease activity, extra-articular disease, or in disability, fatigue, depression, or pain scores were observed. The most common reasons for smoking were emotional support (45.8%), nicotine craving (30.5%) and pain control (25.2%). The Fagerström score revealed mild, moderate and severe nicotine dependence in 67.5%, 24.4%, and 7.5%, respectively. Conclusion: One in three patients with RA actively smoked. Those who smoked had more pain, anxiety, and depression but with low nicotine dependency scores. Contribution: The approach to tobacco cessation should occur in parallel with optimal pain, behavioural support and disease control.
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1)
Open AccessCigarette smoking habits and attitudes among rheumatoid arthritis patients at a tertiary centre in South Africa
Background: People living with rheumatoid arthritis (RA) who smoke cigarettes are known to have worse outcomes with regard to disease control, extra-articular complications and comorbidities. Data regarding this from sub-Saharan Africa is lacking. This study aims to describe the prevalence of cigarette smoking and explore disease control, comorbidities and attitudes of smoking among RA patients in an outpatient clinic at a tertiary hospital. Methods: A cross-sectional study of consenting adult outpatients with RA was conducted. Demographic, clinical and patient-reported outcome measures, together with a questionnaire about smoking and Fagerström test for nicotine dependence, were collated. Results: Of 632 patients (536 female participants), the mean (standard deviation) age and disease duration were 55.4 (13.0) and 10.1 (9.3) years, and 74.1% had two or more comorbidities. Of 218 (34.5%) smokers, more men smoked (p = 0.0002). Compared to non-smokers, smokers had lower body mass index (p = 0.01), higher incidence of chronic obstructive pulmonary disease (p < 0.005) and rheumatoid factor positivity (p = 0.006), and higher anxiety scores (p = 0.048) with more impairment in usual activities (p = 0.05). No significant differences in disease activity, extra-articular disease, or in disability, fatigue, depression, or pain scores were observed. The most common reasons for smoking were emotional support (45.8%), nicotine craving (30.5%) and pain control (25.2%). The Fagerström score revealed mild, moderate and severe nicotine dependence in 67.5%, 24.4%, and 7.5%, respectively. Conclusion: One in three patients with RA actively smoked. Those who smoked had more pain, anxiety, and depression but with low nicotine dependency scores. Contribution: The approach to tobacco cessation should occur in parallel with optimal pain, behavioural support and disease control.
- Open Access
- 3 October 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (10) , e2669
South African Rheumatism and Arthritis Association 2024 guidelines for the management of peripheral spondyloarthritis
Peripheral spondyloarthritis (SpA) includes psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated arthritis, reactive arthritis and undifferentiated peripheral SpA. These South African guidelines offer information on diagnosis, assessment and therapy of peripheral SpA. Emphasis is placed on a multidisciplinary team, and a treat-to-target strategy with escalation of therapy if the target of minimal or very low disease activity is achieved. Screening for and treatment of comorbidities are paramount.
- 3 October 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (10) , e2669
Open AccessSouth African Rheumatism and Arthritis Association 2024 guidelines for the management of peripheral spondyloarthritis
Peripheral spondyloarthritis (SpA) includes psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated arthritis, reactive arthritis and undifferentiated peripheral SpA. These South African guidelines offer information on diagnosis, assessment and therapy of peripheral SpA. Emphasis is placed on a multidisciplinary team, and a treat-to-target strategy with escalation of therapy if the target of minimal or very low disease activity is achieved. Screening for and treatment of comorbidities are paramount.
- Open Access
- 3 October 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (10) , e2668
South African Rheumatism and Arthritis Association 2024 guidelines for the management of axial spondyloarthritis
Early diagnosis and prompt treatment initiation are essential in the management of axial spondyloarthritis (axSpA), also known as ankylosing spondylitis, remembering that underdiagnosis and overdiagnosis of axSpA are common. These South African guidelines offer screening tools and details of useful investigations, including imaging. Care of the axSpA patient requires a multidisciplinary holistic approach emphasising lifestyle interventions, particularly exercise, smoking cessation and psychosocial support. The ankylosing spondylitis disease activity score is recommended as a measure of disease activity, and a stepwise algorithm for therapy is provided. Screening for comorbidities and vaccination is advised.
- 3 October 2024
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 114 (10) , e2668
Open AccessSouth African Rheumatism and Arthritis Association 2024 guidelines for the management of axial spondyloarthritis
Early diagnosis and prompt treatment initiation are essential in the management of axial spondyloarthritis (axSpA), also known as ankylosing spondylitis, remembering that underdiagnosis and overdiagnosis of axSpA are common. These South African guidelines offer screening tools and details of useful investigations, including imaging. Care of the axSpA patient requires a multidisciplinary holistic approach emphasising lifestyle interventions, particularly exercise, smoking cessation and psychosocial support. The ankylosing spondylitis disease activity score is recommended as a measure of disease activity, and a stepwise algorithm for therapy is provided. Screening for comorbidities and vaccination is advised.
- Open Access
- 13 December 2023
- Published by Frontiers Media SA in Frontiers in Musculoskeletal Disorders
- Vol. 1, 1281548
Screening practices, efficacy, safety and adherence to biologic therapies in a South African tertiary hospital
Introduction: The high cost and concern of adverse events, particularly infections, limit the use of biologic therapies. We undertook this retrospective study to document their use for immune-mediated diseases, and explore the screening practices, efficacy, safety, and adherence to bDMARDs in a tertiary hospital.Methods: A folder review of all adult and paediatric patients treated for IMDs with bDMARDs. Changes in disease activity were measured by disease-specific tools at 6, 12, 24-months and at the last available visit, and patient adherence to bDMARDs was explored by folder and pharmacy record review.Results: We studied 120 folders; 145 bDMARDs were prescribed (23 patients switched bDMARD). BDMARDs prescribed included tumour necrosis factor inhibitors (TNFi) (76), rituximab (54), tocilizumab (9), anakinra (3), abatacept (1), ustekinumab (1) and tofacitinib (1). The vast majority of patients had an excellent response and achieved low disease activity or remission at their last available visit. Adverse events included severe infection (9) including two cases of tuberculosis (TB), mild skin reaction (6) and severe infusion reactions (4). Therapy was discontinued in 13 patients, most commonly due to infection (5), lack of response (4), or poor adherence (3). Poor adherence was noted in 8/120 (6.7%). Complete latent TB infection screening was performed in only 35 patients (29.2%). Screening for Hepatitis B, C and HIV was performed in 28 (23.3%), 62 (51.7%) and 61 (50.8%) patients, respectively. Only 20.8% and 20.0% received the influenza and pneumococcal vaccination.Discussion and conclusion: Biologic therapy was effective, and the most important serious adverse effect was infection, which was significantly associated with TNFi therapy. Vaccination and screening for TB, viral hepatitis and HIV was suboptimal. Of concern, poor adherence to bDMARDs was frequently encountered.
- 13 December 2023
- Published by Frontiers Media SA in Frontiers in Musculoskeletal Disorders
- Vol. 1, 1281548
Open AccessScreening practices, efficacy, safety and adherence to biologic therapies in a South African tertiary hospital
Introduction: The high cost and concern of adverse events, particularly infections, limit the use of biologic therapies. We undertook this retrospective study to document their use for immune-mediated diseases, and explore the screening practices, efficacy, safety, and adherence to bDMARDs in a tertiary hospital.Methods: A folder review of all adult and paediatric patients treated for IMDs with bDMARDs. Changes in disease activity were measured by disease-specific tools at 6, 12, 24-months and at the last available visit, and patient adherence to bDMARDs was explored by folder and pharmacy record review.Results: We studied 120 folders; 145 bDMARDs were prescribed (23 patients switched bDMARD). BDMARDs prescribed included tumour necrosis factor inhibitors (TNFi) (76), rituximab (54), tocilizumab (9), anakinra (3), abatacept (1), ustekinumab (1) and tofacitinib (1). The vast majority of patients had an excellent response and achieved low disease activity or remission at their last available visit. Adverse events included severe infection (9) including two cases of tuberculosis (TB), mild skin reaction (6) and severe infusion reactions (4). Therapy was discontinued in 13 patients, most commonly due to infection (5), lack of response (4), or poor adherence (3). Poor adherence was noted in 8/120 (6.7%). Complete latent TB infection screening was performed in only 35 patients (29.2%). Screening for Hepatitis B, C and HIV was performed in 28 (23.3%), 62 (51.7%) and 61 (50.8%) patients, respectively. Only 20.8% and 20.0% received the influenza and pneumococcal vaccination.Discussion and conclusion: Biologic therapy was effective, and the most important serious adverse effect was infection, which was significantly associated with TNFi therapy. Vaccination and screening for TB, viral hepatitis and HIV was suboptimal. Of concern, poor adherence to bDMARDs was frequently encountered.
- Open Access
- 18 July 2022
- Vol. 28 (2)
Interstitial lung disease in patients with connective tissue disease: Subtypes, clinical features and comorbidities in the Western Cape, South Africa.
Interstitial lung disease (ILD) is highly prevalent in patients with connective tissue disease (CTD) and is poorly characterised in South Africa. To describe the clinical, serological and radiological features of CTD-ILD and their associations in patients attending a tertiary referral hospital. A cross-sectional study collating clinical, serological and radiological features of CTD-ILD in patients attending rheumatology and respiratory outpatient clinics in a tertiary referral hospital. Of 124 CTD-ILD patients, 37 (29.8%) had rheumatoid arthritis (RA), 32 (25.8%) systemic sclerosis (SSc) and 55 (44.4%) other autoimmune connective tissue diseases (OCTD). Most patients were female (86.3%), of mixed racial ancestry (75.0%), and the median age was 55 years. Nonspecific interstitial pneumonia (NSIP) was the most common ILD pattern (63.7%), followed by usual interstitial pneumonia (UIP) (26.6%). Overall, 60.5% were current or past smokers, 33.1% had previous pulmonary tuberculosis infection, and 75.6% had gastro-oesophageal reflux disease. Patients with RA were older, had similar frequencies of NSIP and UIP, and had significantly better pulmonary function tests than the SSc and OCTD groups. Within three years of CTD diagnosis, two-thirds of the SSc and OCTD patients and almost half of the RA patients had developed ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT). No case of acute pneumonitis was documented in CTD-ILD patients treated with methotrexate (MTX). We suggest routine HRCT in all newly diagnosed CTD patients, particularly those with SSc and OCTD, where more than two-thirds of the patients had developed ILD within three years of their CTD. The use of MTX was not associated with the development of acute pneumonitis in patients with ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT).Smoking, environmental toxins, gastro-oesophogeal reflux and previous pulmonary tuberculosis infection were significant comorbidities in CTD-ILD patients.Early screening of ILD with HRCT is recommended, particularly in SSc.Use of MTX before and after ILD diagnosis was not associated with acute pneumonitis.
- 18 July 2022
- Vol. 28 (2)
Open AccessInterstitial lung disease in patients with connective tissue disease: Subtypes, clinical features and comorbidities in the Western Cape, South Africa.
Interstitial lung disease (ILD) is highly prevalent in patients with connective tissue disease (CTD) and is poorly characterised in South Africa. To describe the clinical, serological and radiological features of CTD-ILD and their associations in patients attending a tertiary referral hospital. A cross-sectional study collating clinical, serological and radiological features of CTD-ILD in patients attending rheumatology and respiratory outpatient clinics in a tertiary referral hospital. Of 124 CTD-ILD patients, 37 (29.8%) had rheumatoid arthritis (RA), 32 (25.8%) systemic sclerosis (SSc) and 55 (44.4%) other autoimmune connective tissue diseases (OCTD). Most patients were female (86.3%), of mixed racial ancestry (75.0%), and the median age was 55 years. Nonspecific interstitial pneumonia (NSIP) was the most common ILD pattern (63.7%), followed by usual interstitial pneumonia (UIP) (26.6%). Overall, 60.5% were current or past smokers, 33.1% had previous pulmonary tuberculosis infection, and 75.6% had gastro-oesophageal reflux disease. Patients with RA were older, had similar frequencies of NSIP and UIP, and had significantly better pulmonary function tests than the SSc and OCTD groups. Within three years of CTD diagnosis, two-thirds of the SSc and OCTD patients and almost half of the RA patients had developed ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT). No case of acute pneumonitis was documented in CTD-ILD patients treated with methotrexate (MTX). We suggest routine HRCT in all newly diagnosed CTD patients, particularly those with SSc and OCTD, where more than two-thirds of the patients had developed ILD within three years of their CTD. The use of MTX was not associated with the development of acute pneumonitis in patients with ILD. Clinical features, chest X-rays and pulmonary function tests correlated poorly with high-resolution computerised tomography (HRCT).Smoking, environmental toxins, gastro-oesophogeal reflux and previous pulmonary tuberculosis infection were significant comorbidities in CTD-ILD patients.Early screening of ILD with HRCT is recommended, particularly in SSc.Use of MTX before and after ILD diagnosis was not associated with acute pneumonitis.
- Open Access
- 16 June 2020
- Published by Springer Nature in BMC Rheumatology
- Vol. 4 (1) , 1-16
Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country
Background: It is plausible that optimal cardiovascular disease (CVD) risk management differs in patients with rheumatoid arthritis (RA) from low or middle income compared to high income populations. This study aimed at producing evidence-based points to consider for CVD prevention in South African RA patients. Methods: Five rheumatologists, one cardiologist and one epidemiologist with experience in CVD risk management in RA patients, as well as two patient representatives, two health professionals and one radiologist, one rheumatology fellow and 11 rheumatologists that treat RA patients regularly contributed. Systematic literature searches were performed and the level of evidence was determined according to standard guidelines. Results: Eighteen points to consider were formulated. These were grouped into 6 categories that comprised overall CVD risk assessment and management (n = 4), and specific interventions aimed at reducing CVD risk including RA control with disease modifying anti-rheumatic drugs, glucocorticoids and non-steroidal anti-inflammatory drugs (n = 3), lipid lowering agents (n = 8), antihypertensive drugs (n = 1), low dose aspirin (n = 1) and lifestyle modification (n = 1). Each point to consider differs partially or completely from recommendations previously reported for CVD risk management in RA patients from high income populations. Currently recommended CVD risk calculators do not reliably identify South African black RA patients with very high-risk atherosclerosis as represented by carotid artery plaque presence on ultrasound. Conclusions: Our findings indicate that optimal cardiovascular risk management likely differs substantially in RA patients from low or middle income compared to high income populations. There is an urgent need for future multicentre longitudinal studies on CVD risk in black African patients with RA.
- 16 June 2020
- Published by Springer Nature in BMC Rheumatology
- Vol. 4 (1) , 1-16
Open AccessPoints to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country
Background: It is plausible that optimal cardiovascular disease (CVD) risk management differs in patients with rheumatoid arthritis (RA) from low or middle income compared to high income populations. This study aimed at producing evidence-based points to consider for CVD prevention in South African RA patients. Methods: Five rheumatologists, one cardiologist and one epidemiologist with experience in CVD risk management in RA patients, as well as two patient representatives, two health professionals and one radiologist, one rheumatology fellow and 11 rheumatologists that treat RA patients regularly contributed. Systematic literature searches were performed and the level of evidence was determined according to standard guidelines. Results: Eighteen points to consider were formulated. These were grouped into 6 categories that comprised overall CVD risk assessment and management (n = 4), and specific interventions aimed at reducing CVD risk including RA control with disease modifying anti-rheumatic drugs, glucocorticoids and non-steroidal anti-inflammatory drugs (n = 3), lipid lowering agents (n = 8), antihypertensive drugs (n = 1), low dose aspirin (n = 1) and lifestyle modification (n = 1). Each point to consider differs partially or completely from recommendations previously reported for CVD risk management in RA patients from high income populations. Currently recommended CVD risk calculators do not reliably identify South African black RA patients with very high-risk atherosclerosis as represented by carotid artery plaque presence on ultrasound. Conclusions: Our findings indicate that optimal cardiovascular risk management likely differs substantially in RA patients from low or middle income compared to high income populations. There is an urgent need for future multicentre longitudinal studies on CVD risk in black African patients with RA.
- 27 May 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (7) , 2039-2042
Navigating COVID-19 in the developing world
- 27 May 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (7) , 2039-2042
Navigating COVID-19 in the developing world
- Open Access
- 16 April 2019
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 17 (1) , 1-10
Living with systemic lupus erythematosus in South Africa: a bitter pill to swallow
Systemic lupus erythematosus (SLE) often has a profound negative impact on health-related quality of life (HRQoL). In the absence of any qualitative studies in sub-Saharan Africa, we undertook a study to explore living experiences, perceptions and unmet needs of South African patients with SLE. Twenty-five women with SLE consented to participate in the study. They underwent individual in-depth interviews exploring their physical concerns, emotional health, sexual well-being and fertility. NVivo software was used for analysis. Participants were either of black ancestry or mixed racial ancestry, mainly indigent with only a quarter gainfully employed. Living with pain was the most common complaint, negatively impacting on activities of daily living (ADL), family expectations, social life, sleep and intimacy. Most participants expressed challenges of living with fatigue, and many felt their fatigue was misconstrued as being ‘simply lazy’. This pernicious fatigue had negative consequences on many facets of ADL, including caring for dependants, job sustainability and sexual well-being. All participants experienced low emotional states, often associated with suicidal ideations. Many experienced difficulties with fertility and childbearing and these were exacerbated in many instances by the pessimism of health care providers, resulting in confusion and depression. Physical disfigurements resulting from lupus-associated alopecia and rashes and corticosteroid-induced weight fluctuations were a major concern. These changes often affected self-image and libido, leading to strained personal relationships. Coping mechanisms that participants adopted included intense spiritual beliefs, ‘pushing through the difficult times’ and use of alternative therapies to relief symptoms was common. A poor understanding of SLE on the part of participant’s family and the community, coupled with the unpredictable course of the disease, exacerbated frustration and social exclusion. For most, limited income, lack of basic services, family dependencies, and comorbid diseases, such as human immune deficiency virus (HIV), exacerbated the daily negative SLE experiences. In this study of mainly indigent South African women, SLE is associated with complex, chronic and challenging life experiences. The chronic relapsing and unpredictable nature of the disease, poor understanding and acceptance of SLE, compounded by a background of poverty, inadequate social support structures, negatively impact on a range of personal, social and vocational daily life experiences. Improved access to psychosocial services and SLE education might result in better outcomes. (Ethics Project identification code: 275/2016 and M160633 registered 10 & 29 August 2016).
- 16 April 2019
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 17 (1) , 1-10
Open AccessLiving with systemic lupus erythematosus in South Africa: a bitter pill to swallow
Systemic lupus erythematosus (SLE) often has a profound negative impact on health-related quality of life (HRQoL). In the absence of any qualitative studies in sub-Saharan Africa, we undertook a study to explore living experiences, perceptions and unmet needs of South African patients with SLE. Twenty-five women with SLE consented to participate in the study. They underwent individual in-depth interviews exploring their physical concerns, emotional health, sexual well-being and fertility. NVivo software was used for analysis. Participants were either of black ancestry or mixed racial ancestry, mainly indigent with only a quarter gainfully employed. Living with pain was the most common complaint, negatively impacting on activities of daily living (ADL), family expectations, social life, sleep and intimacy. Most participants expressed challenges of living with fatigue, and many felt their fatigue was misconstrued as being ‘simply lazy’. This pernicious fatigue had negative consequences on many facets of ADL, including caring for dependants, job sustainability and sexual well-being. All participants experienced low emotional states, often associated with suicidal ideations. Many experienced difficulties with fertility and childbearing and these were exacerbated in many instances by the pessimism of health care providers, resulting in confusion and depression. Physical disfigurements resulting from lupus-associated alopecia and rashes and corticosteroid-induced weight fluctuations were a major concern. These changes often affected self-image and libido, leading to strained personal relationships. Coping mechanisms that participants adopted included intense spiritual beliefs, ‘pushing through the difficult times’ and use of alternative therapies to relief symptoms was common. A poor understanding of SLE on the part of participant’s family and the community, coupled with the unpredictable course of the disease, exacerbated frustration and social exclusion. For most, limited income, lack of basic services, family dependencies, and comorbid diseases, such as human immune deficiency virus (HIV), exacerbated the daily negative SLE experiences. In this study of mainly indigent South African women, SLE is associated with complex, chronic and challenging life experiences. The chronic relapsing and unpredictable nature of the disease, poor understanding and acceptance of SLE, compounded by a background of poverty, inadequate social support structures, negatively impact on a range of personal, social and vocational daily life experiences. Improved access to psychosocial services and SLE education might result in better outcomes. (Ethics Project identification code: 275/2016 and M160633 registered 10 & 29 August 2016).